European journal of cancer (Oxford, England : 1990)

publication venue for

Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. 1991
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition. 2023
The regulation of CD73 in non-small cell lung cancer.. 170. 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302.. 170. 2022
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment.. 168. 2022
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. 163. 2022
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.. 159. 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.. 157. 2021
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.. 156. 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.. 157. 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.. 155. 2021
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.. 150. 2021
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.. 146. 2021
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.. 144. 2020
Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways.. 144. 2020
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools.. 143. 2020
Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.. 138. 2020
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.. 135. 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.. 130. 2020
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.. 126. 2020
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.. 125. 2020
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial.. 125. 2019
Clinical features of neuroendocrine prostate cancer.. 121. 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.. 119. 2019
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.. 114. 2019
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.. 114. 2019
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.. 109. 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.. 109. 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.. 108. 2019
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.. 106. 2018
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.. 104. 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.. 101. 2018
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.. 99. 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.. 94. 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.. 94. 2018
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.. 89. 2017
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma.. 86. 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.. 86. 2017
Menopausal hormone therapy and cancer risk: An overestimated risk?. 84. 2017
Health-related quality of life results from the phase III CheckMate 067 study.. 82. 2017
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.. 80. 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.. 76. 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.. 73. 2017
Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24].. 68. 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.. 64. 2016
Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis.. 63. 2016
RECIST 1.1-Update and clarification: From the RECIST committee.. 62. 2016
Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours.. 59. 2016
Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study.. 51. 2015
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas.. 51. 2015
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.. 51. 2015
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.. 51. 2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.. 51. 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.. 51. 2015
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.. 50. 2014
Genomics-based early-phase clinical trials in oncology: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.. 50. 2014
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.. 50. 2014
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.. 50. 2014
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.. 50. 2014
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.. 50. 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.. 49. 2013
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.. 49. 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.. 49. 2013
Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy.. 49. 2013
Design and conduct of early clinical studies of two or more targeted anticancer therapies: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.. 49. 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.. 49. 2013
Assessment of the Memorial Sloan-Kettering Cancer Center nomogram to predict sentinel lymph node metastases in a Dutch breast cancer population.. 49. 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.. 49. 2012
Patterns of deregulation of insulin growth factor signalling pathway in paediatric and adult gastrointestinal stromal tumours.. 48. 2012
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.. 48. 2012
Long term renal toxicity of ifosfamide in adult patients--5 year data.. 48. 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology.. 48. 2012
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.. 48. 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.. 48. 2011
Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy.. 48. 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.. 48. 2011
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.. 47. 2011
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology.. 47. 2010
High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma.. 47. 2010
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.. 46. 2010
Amplification of epidermal growth factor receptor gene in renal cell carcinoma.. 46. 2010
Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.. 46. 2010
The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.. 46. 2010
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.. 46. 2010
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.. 46. 2009
Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients.. 45. 2009
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion.. 45. 2009
Management and outcome of stage 3 neuroblastoma.. 45. 2008
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer.. 44. 2008
Management of malignant bowel obstruction.. 44. 2008
Prostate volume and adverse prostate cancer features: fact not artifact.. 43. 2007
UbcH10 is overexpressed in malignant breast carcinomas.. 43. 2007
Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).. 44. 2007
Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).. 44. 2007
Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973).. 43. 2006
Quality assurance of thoracic radiotherapy in EORTC 08941: a randomised trial of surgery versus thoracic radiotherapy in patients with stage IIIA non-small-cell lung cancer (NSCLC) after response to induction chemotherapy.. 42. 2006
Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European organization for research and treatment of cancer (EORTC 08984).. 42. 2006
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.. 42. 2005
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.. 41. 2005
Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.. 41. 2005
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.. 40. 2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.. 40. 2004
Studies with cytotoxic agents suggest that apoptosis is not a major determinant of clonogenic death in neuroblastoma cells.. 39. 2003
Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. an EORTC phase II study (EORTC 08958).. 39. 2003
Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).. 39. 2003
Does use of alternative medicine predict survival from cancer?. 39. 2003
The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992).. 39. 2003
Phase II trial of ZD0473 as second-line therapy in mesothelioma.. 38 Suppl 8. 2002
Tamoxifen for primary breast cancer prevention in BRCA heterozygotes.. 38 Suppl 6. 2002
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.. 38. 2002
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.. 38. 2002
Overview of past, present and future of the EORTC Lung Cancer Group. European Organisation for Research and Treatment of Cancer.. 38 Suppl 4. 2002
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.. 36. 2000
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.. 36. 2000
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract.. 36 Suppl 2. 2000
Prevalence of complementary therapy use by women with breast cancer. A population-based survey.. 36. 2000
Radiotherapy of the brain in elderly patients. arbiter:. 36. 2000
Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice.. 36. 2000
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.. 35. 1999
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast.. 33. 1997
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.. 33. 1997
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.. 33. 1997
Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.. 33. 1997
Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma.. 33. 1997
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group.. 33. 1997
Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biological markers.. 33. 1997
Differential responses to chemoimmunotherapy in patients with metastatic malignant melanoma.. 33. 1997
Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.. 32A. 1996
Effects of suramin on human lung cancer cell lines.. 31A. 1995
High-dose chemotherapy of breast cancer: current status and developmental strategies.. 31A. 1995
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.. 31A Suppl 4. 1995
A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.. 30A. 1994
In vitro sequence-dependent synergistic effect of suramin and camptothecin.. 30A. 1994
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.. 30A. 1994
Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures.. 29A. 1993
Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).. 29A Suppl 1. 1993
Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group.. 28. 1992
Effects of extracellular matrix on the response of endothelial cells to radiation in vitro.. 28A. 1992
Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.. 28A. 1992
Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients.. 27. 1991
Cisplatin and teniposide chemotherapy for advanced non-small cell lung cancer.. 27. 1991
Differential c-myc protein expression in Burkitt's lymphomas and EBV-transformed lymphoblastoid lines.. 27. 1991
Haemodynamic effects of recombinant interleukin-2 administered by constant infusion.. 27. 1991
Methodology in anti-emetic trials.. 27 Suppl 1. 1991
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.. 27. 1991
Multimodality treatment of malignant germ cell tumours of the mediastinum.. 27. 1991
Pilot study of teniposide in combination chemotherapy for small cell lung cancer.. 27. 1991
Antiproliferative effects of suramin on androgen responsive tumour cells.. 26. 1990
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. 2019
Comment on: Does use of alternative medicine predict survival from cancer? Eur J Cancer 2003, 39, 372-377. 2003
Unusual clonal evolution during blast crisis of chronic myeloid leukaemia (CML). 1994
Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. 2016
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel. 2014
Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. 2008
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. 2008
Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. 2008
Magnetic resonance imaging in breast cancer: is seeing always believing?. 41. 2005
Continued refinement in the treatment of germ cell tumour patients.. 27. 1991
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. 2023
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. 2022
Impact of ¹⁸F-Fluorodeoxyglucose positron emission tomography on management of cancer of unknown primary: systematic review and meta-analysis. 2021
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. 2021
First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. 2021
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. 2020
Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. 2019
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. 2017
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. 2017
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. 2016
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. 2016
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. 2016
Are we ready to predict late effects? A systematic review of clinically useful prediction models. 2015
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). 2014
Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. 2013
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. 2011
Targeted agents: how to select the winners in preclinical and early clinical studies? 2011
Novel treatments for castration-resistant prostate cancer. 2011
Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. 2011
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. 2011
Lung tumours with neuroendocrine differentiation. 2009
Biology and management of malignant pleural mesothelioma. 2006
What's new in the treatment of advanced prostate cancer? 2003
The role of new agents in the treatment of non-small cell lung cancer. 2002
PET imaging of gene expression. 2002
Small animal imaging. current technology and perspectives for oncological imaging. 2002
Current perspectives in muscle invasive bladder cancer. 2002
State of the art in systemic treatment of lung cancer. 2001
Systemic treatment and new developments in advanced prostate cancer. 2001
Pathology of AIDS-related lymphomas and other AIDS-defining neoplasms. 2001
Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? 1998
Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? 1996
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. 1996
MDR1/P-glycoprotein expression in colorectal cancer. 1995
Multidrug resistance in breast cancer: mechanisms, strategies. 1995
Should clinicians be concerned about the carcinogenic potential of tamoxifen? 1994
Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist. 1993
Multidrug resistance from the clinical point of view. 1991

VIVO Weill Cornell Medical College

European journal of cancer (Oxford, England : 1990) Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)